Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gyros Continues Positive Trend in 2011

Published: Tuesday, May 10, 2011
Last Updated: Tuesday, May 10, 2011
Bookmark and Share
Major biopharmaceutical companies continued to demonstrate their confidence in the Gyros immunoassay platform, with existing accounts investing in additional Gyrolab™ workstations at different sites on both sides of the Atlantic.

The North American market, containing many of the key players involved in global efforts to develop novel biotherapeutics, had a particularly strong start with a revenue growth of 100% compared to the same period in 2010. The number of service providers, such as CRO’s, implementing Gyrolab workstations into their projects also increased.

Commenting on the announcement, Erik Walldén, President and Chief Executive Officer of Gyros AB, said:  “This positive trend confirms that our immunoassay platform is increasingly regarded as an established standard for many time-critical workflows in biotherapeutic development processes. This recognition is also reflected by the interest shown in our annual Gyrolab seminars, held in the USA and Europe, which attract scientists from across the industry.”  Mr. Walldén continued, “Our growing installed base means significant growth in orders for consumables, especially our unique Gyrolab CDs in which the immunoassay steps take place under control of the workstation. Moving forward, Gyros is in an excellent position to set the industry standard for transforming the performance of immunoassays wherever they are utilized within the biopharmaceutical industry.”

The Company’s open, automated platform supports time-critical workflows in the biopharmaceutical industry, boosting productivity and cutting time to result. Automatically running immunoassays at nanoliter scale not only ensures faster development times, but also saves labor, sample and reagents. Assays are readily transferred downstream into GxP environments and between different sites, greatly facilitating collaborations between biopharmaceutical companies and their service providers. Having established the platform in the USA and Europe, Gyros is now focused on building awareness in Asia Pacific, where the Company recently announced that it has appointed a network of distributors.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gyros Announces Changes to its Management Team
Dr. Jon-Sverre Schanche becomes Chief Technology Officer and Vice President Technical Affairs.
Monday, October 24, 2011
Gyros Wins SwedenBIO Award 2011
Company selected to receive the award based on the international success of the Gyros immunoassay platform.
Friday, May 27, 2011
Gyros platform enters leading US Clinical Research Organization
CEDRA Corporation, a division of Worldwide Clinical Trials, invests in Gyrolab workstation
Tuesday, March 16, 2010
Gyros Platform Ramps Up Immunoassay Capacity at ICON Development Solutions
CRO purchases third Gyrolab workstation to develop and run immunoassays.
Friday, March 12, 2010
Gyros and SCRUM Sign Distribution Agreement for the Japanese Market
SCRUM will market, sell and fully support the Gyros product range, within the Japanese life-science market industries.
Wednesday, February 17, 2010
Gyros has Completed the Separate Sales of two Microfluidic System Platforms
Gyros platform for protein quantification is purchased by AstraZeneca and Cambridge Antibody Technology.
Wednesday, August 09, 2006
Gyros Awarded Frost & Sullivan Technology of the Year Award
The award recognizes the company’s technology development and overall technical excellence.
Wednesday, November 16, 2005
Gyros AB licenses technology to Cellectricon AB

Tuesday, April 15, 2003
Gyros expands with German office

Monday, December 02, 2002
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Puttng Cells Through Their Paces
An obstacle course for human lung cells could be the answer for better testing the effectiveness of potential new drugs.
Dolomite Bio’s Single Cell RNA-Seq System Enables High Speed Encapsulation
Dolomite Bio has developed the Single-Cell RNA-Seq System for efficient, high throughput single cell transcriptomics.
NASA's DNA Sequencing in Space is a Success
DNA has been sequenced in space for the first time ever for the Biomolecule Sequencer investigation, using the MinION sequencing device.
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Lab-on-a-Stick: Miniaturised Clinical Testing For Fast Detection Of Antibiotic Resistance
A portable power-free test for the rapid detection of bacterial resistance to antibiotics has been developed by academics at Loughborough University and the University of Reading.
Measuring Chemistry on a Chip
Researchers developing chemical sensor chip for sample analysis in a lab or monitoring air and water quality in the field.
Automating Genetic Analysis
Researchers are looking to have computers help perform genetic analysis when scientists study a patient's genome to diagnose a disease.
Microchip Tech Improves Nanomaterial Safety Screening
Platform developed at UCLA uses lab-on-a-chip technology to predict how hazardous engineered nanomaterials might be.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!